KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

GoodRx Holdings (GDRX) EBITDA Margin (2019 - 2025)

GoodRx Holdings' EBITDA Margin history spans 7 years, with the latest figure at 11.65% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 249.0% year-over-year to 11.65%; the TTM value through Dec 2025 reached 10.98%, up 267.0%, while the annual FY2025 figure was 11.51%, 263.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 11.65% at GoodRx Holdings, up from 7.46% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 13.2% in Q2 2025 and bottomed at 21.3% in Q3 2023.
  • The 5-year median for EBITDA Margin is 5.83% (2023), against an average of 3.41%.
  • The largest YoY upside for EBITDA Margin was 20053bps in 2021 against a maximum downside of -3585bps in 2021.
  • A 5-year view of EBITDA Margin shows it stood at 5.51% in 2021, then tumbled by -83bps to 0.94% in 2022, then plummeted by -1086bps to 9.3% in 2023, then skyrocketed by 198bps to 9.15% in 2024, then grew by 27bps to 11.65% in 2025.
  • Per Business Quant, the three most recent readings for GDRX's EBITDA Margin are 11.65% (Q4 2025), 7.46% (Q3 2025), and 13.2% (Q2 2025).